Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, sequential design phase 1/2 trial of GEB-101 single intrastromal injection in US for treatment of TGFBI corneal dystrophy

Next Previous
Trial Profile

A multicenter, sequential design phase 1/2 trial of GEB-101 single intrastromal injection in US for treatment of TGFBI corneal dystrophy

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GEB 101 (Primary)
  • Indications Corneal disorders; Hereditary corneal dystrophies
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CLARITY

Most Recent Events

  • 16 Jan 2026 According to a GenEditBio media release, U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate phase 1/2 CLARITY trial activities for GEB-101 for TGFBI corneal dystrophy and patient enrollment is expected to commence in the second quarter of this year after site activation in the U.S.
  • 16 Jan 2026 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top